Evaluate effect of DAADs on covid-19 disease.
If Chronic HCV patients who already received DAADs are protected against covid 19 and
considered to be immune or not And if DAADS can be used in ttt of covid 19
Drug: DAAD Compound
Sofosbuvir , Daclatasvir and ribavirin
Inclusion Criteria:
1. HCV patient with or without LC.
2. >18 years old.
3. Received DAADs at 2019.
Exclusion Criteria:
1. Combined HCV and HIV infected patients.
2. Combined HCV and HBV infected patients.
3. < 18 years old.
4. Pregnant or breast-feeding patients.
5. Patients with autoimmune disease.
6. Patients with multiorgan failure, active cancer, renal insufficiency.
7. Patients received immunosuppressive drugs.
8. Immune compromised patients.
9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.
Eman Adel
01096883754
emanadel9594@gmail.com
Nahed Ahmed
0 100 361 1626
nahedmak@yahoo.com